A recombinant chimera comprising the R1 and R2 repeat regions of M.hyopneumoniae P97 and the N-terminal region of A. pleuropneumoniae ApxIII elicits immune responses

被引:13
作者
Lee, Seung Heon [1 ]
Lee, Seungwoo [1 ]
Chae, Chanhee [1 ]
Ryu, Doug-Young [1 ]
机构
[1] Seoul Natl Univ, Coll Vet Med, Seoul 151742, South Korea
关键词
Actinobacillus pleuropneumoniae; ApxIII; Mycoplasma hyopneumoniae; P97; Recombinant chimera; Vaccine; MYCOPLASMA-HYOPNEUMONIAE INFECTION; ACTINOBACILLUS-PLEUROPNEUMONIAE; MYCOBACTERIUM-TUBERCULOSIS; VACCINE STRAIN; ADHESIN GENE; B-SUBUNIT; PROTEIN; IMMUNOGENICITY; EXPRESSION; PNEUMONIA;
D O I
10.1186/1746-6148-10-43
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Background: Infection by Mycoplasma hyopneumoniae and Actinobacillus pleuropneumoniae, either alone or together, causes serious respiratory diseases in pigs. Results: To develop an efficient multi-disease subunit vaccine against these pathogens, we produced a chimeric protein called Ap97, which comprises a deletion derivative of the N-terminal region of the A. pleuropneumoniae ApxIII toxin (ApxN) and the R1 and R2 repeats of M. hyopneumoniae P97 adhesin (P97C), using an E. coli expression system. The levels of both IgG1 and IgG2a isotypes specific for ApxN and P97C in the sera of Ap97-immunized mice increased, and Ap97 induced the secretion of IL-4 and IFN-gamma. by mouse splenocytes. Antisera from mice and pigs immunized with Ap97 readily reacted with both native ApxIII and P97 proteins. In addition, immunization with the Ap97 vaccine effectively protected pigs against challenge with both pathogens. Conclusions: These findings suggest that Ap97 confers immunogenicity, and is an effective vaccine that protects pigs against infection by M. hyopneumoniae and A. pleuropneumoniae.
引用
收藏
页数:12
相关论文
共 55 条
  • [1] Immunogenicity of Actinobacillus ApxIA toxin epitopes fused to the E-coli heat-labile enterotoxin B subunit
    Bagdasarian, MM
    Nagai, M
    Frey, J
    Bagdasarian, M
    [J]. VACCINE, 1999, 17 (05) : 441 - 447
  • [2] Actinobacillus pleuropneumoniae:: pathobiology and pathogenesis of infection
    Bossé, JT
    Janson, H
    Sheehan, BJ
    Beddek, AJ
    Rycroft, AN
    Kroll, JS
    Langford, PR
    [J]. MICROBES AND INFECTION, 2002, 4 (02) : 225 - 235
  • [3] Vaccine delivery to animals
    Bowersock, TL
    Martin, S
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 1999, 38 (02) : 167 - 194
  • [4] Modulation of immune responses in mice to recombinant antigens from PE and PPE families of proteins of Mycobacterium tuberculosis by the Ribi adjuvant
    Chaitra, M. G.
    Nayak, R.
    Shaila, M. S.
    [J]. VACCINE, 2007, 25 (41) : 7168 - 7176
  • [5] MOLECULAR ANALYSIS OF THE ACTINOBACILLUS-PLEUROPNEUMONIAE RTX TOXIN-III GENE-CLUSTER
    CHANG, YF
    SHI, JR
    MA, DP
    SHIN, SJ
    LEIN, DH
    [J]. DNA AND CELL BIOLOGY, 1993, 12 (04) : 351 - 362
  • [6] Evaluation of the immunogenicity of the P97R1 adhesin of Mycoplasma hyopneumoniae as a mucosal vaccine in mice
    Chen, Austen Y.
    Fry, Scott R.
    Forbes-Faulkner, Judy
    Daggard, Grant
    Mukkur, T. K. S.
    [J]. JOURNAL OF MEDICAL MICROBIOLOGY, 2006, 55 (07) : 923 - 929
  • [7] A recombinant chimera composed of repeat region RR1 of Mycoplasma hyopneumoniae adhesin with Pseudomonas exotoxin:: in vivo evaluation of specific IgG response in mice and pigs
    Chen, JR
    Liao, CW
    Mao, SJT
    Weng, CN
    [J]. VETERINARY MICROBIOLOGY, 2001, 80 (04) : 347 - 357
  • [8] Expression of nitric oxide synthase 2 and cyclooxygenase-2 in swine experimentally infected with Actinobacillus pleuropneumoniae
    Cho, WS
    Chae, C
    [J]. VETERINARY PATHOLOGY, 2004, 41 (06) : 666 - 672
  • [9] CIPRIAN A, 1988, CAN J VET RES, V52, P434
  • [10] CONTROL TESTING OF COMBINED VACCINES - A CONSIDERATION OF POTENTIAL PROBLEMS AND APPROACHES
    CORBEL, MJ
    [J]. BIOLOGICALS, 1994, 22 (04) : 353 - 360